Open-label extension data show fasedienol appears well tolerated and steadily improves social anxiety scores with as-needed intranasal use, as Vistagen plans FDA discussions.
|Videos|October 20, 2020
Complementing Your Psychotherapy
Author(s)Shawn Singh, JD
VistaGen Therapeutics CEO Shawn Singh discusses what he and VistaGen are doing to create and improve treatments that complement your practice.
Advertisement
Shawn K. Singh, JD, is the CEO of VistaGen Therapeutics, Inc.
To see more of what VistaGen is doing to improve the medicinal treatments for anxiety and depression, see
Advertisement
Related to this article
Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
Single-dose DT120 ODT delivers rapid, sustained anxiety relief in phase 3 GAD trial, supporting FDA breakthrough path and NDA plans.
Phase 1 driving simulation finds bedtime GlyphAllo for major depressive disorder shows no next-morning driving impairment, while advancing allopregnanolone-based oral treatment development.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Adolescent Brain and Schizophrenia: What Research Reveals About Pruning, Dopamine, and Myelin
2
Exploring a Misuse of Neuroscience: How Biology Has Been Used to Remove Responsibility in Youth
3
Searching for a New TMS Target in Schizophrenia, With Andrew Pines, MD
4
Treating PTSD Among Veterans at Risk for Suicide
5